SCHEMBL1287294

SCHEMBL1287294

COC(=O)c1ccc(CN(C(c2ccccc2)C(C)C)S(=O)(=O)c2ccc(F)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 5/20 0.54
PSEN1 P49768 1/20 0.54
PSEN2 P49810 1/20 0.54
APH1B Q8WW43 1/20 0.54
NCSTN Q92542 1/20 0.54
APH1A Q96BI3 1/20 0.54
PSENEN Q9NZ42 1/20 0.54
BMP1 P13497 3/20 0.49
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
HTT P42858 1/20 0.47
MAPT P10636 2/20 0.45
MMP2 P08253 2/20 0.45
MMP9 P14780 2/20 0.45
MMP8 P22894 2/20 0.45
MMP13 P45452 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10205290 0.88 PSEN1 (0.64) TAS2R14PSEN1PSEN2APH1BNCSTN
SCHEMBL15388033 0.86 PSEN1 (0.54) TAS2R14PSEN1PSEN2APH1BNCSTN
SCHEMBL1674548 0.86 PSEN1 (0.54) TAS2R14PSEN1PSEN2APH1BNCSTN
SCHEMBL5114625 0.85 PSEN1 (0.53) TAS2R14PSEN1PSEN2APH1BNCSTN
SCHEMBL5114629 0.85 PSEN1 (0.53) TAS2R14PSEN1PSEN2APH1BNCSTN
SCHEMBL15396110 0.84 TAS2R14 (0.59) TAS2R14PSEN1PSEN2APH1BNCSTN
SCHEMBL1287987 0.81 PSEN1 (0.60) TAS2R14PSEN1PSEN2APH1BNCSTN
SCHEMBL1287309 0.81 PSEN1 (0.60) TAS2R14PSEN1PSEN2APH1BNCSTN
SCHEMBL1169700 0.80 TAS2R14 (0.75) TAS2R14PSEN1PSEN2APH1BNCSTN
SCHEMBL1287310 0.80 TAS2R14 (0.56) TAS2R14PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310384-A1 Sulfonamide-Containing Compounds THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2013-11-21 US disclosed
US-20130310384-A1 Sulfonamide-Containing Compounds THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2013-11-21 US disclosed
WO-2012047926-A2 SULFONAMIDE-CONTAINING COMPOUNDS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2012-04-12 WO disclosed
WO-2012047926-A2 SULFONAMIDE-CONTAINING COMPOUNDS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310384-A1 Sulfonamide-Containing Compounds BACE1, BACE2, GSAP TAS2R14 3104/4885PSEN1 4/4885PSEN2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.